The PR does not say whether MRK intends to seek US approval via a conventional BLA or via the new 351(k) pathway for FoB’s. Enbrel had 2010 worldwide sales of $7.2B, of which about half was in the US (#msg-59851976).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.